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Abstract
Tissue inhibitor of metalloproteinase 3 (TIMP-3) promoter methylation has been linked to loss of TIMP-3 expression
in various cancers. In this study, we analyzed TIMP-3 gene methylation using MethyLight assay and TIMP-3 mRNA
expression using reverse transcription–polymerase chain reaction analysis in 22 esophageal cancers, 27 gastric
carcinomas, and 7 cancer cell lines. We also analyzed TIMP-3 protein expression by immunohistochemistry and
its association with clinicopathological characteristics in two cohorts of gastric cancer comprising a total of 347 pa-
tients. The TIMP-3 gene was more commonly methylated in adenocarcinomas of the esophagus (9/13) and stom-
ach (9/15) than in the corresponding nonneoplastic mucosa of the esophagus (1/8; P = .024) and stomach (2/14;
P = .021). In gastric cancer patients, TIMP-3 was decreased in a diffuse-type gastric cancer and in cancers with
poor differentiation and was associated with poor survival (P = .04). In summary, we observed frequent TIMP-3
promoter methylation in adenocarcinomas of the esophagus and stomach and the loss of TIMP-3 expression
seems to be of clinical and prognostic relevance in these cancers.
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Introduction
Despite the recent improvements in the diagnosis for adenocarcino-
mas of the esophagus and stomach, most patients are diagnosed at
advanced stages in which the therapeutic options are limited, with
a 5-year survival rate of less than 25% [1–5]. Currently, esophageal
and gastric adenocarcinomas are believed to develop in a stepwise
model of intestinal metaplasia leading to intraepithelial neoplasia
(IEN) and, subsequently, adenocarcinoma. In the esophagus, adeno-
carcinomas develop from Barrett metaplasia that results from a long-
standing history of reflux esophagitis. Approximately 0.5% of
patients per year advance to IEN and Barrett cancer, while the un-
derlying molecular changes are not well understood so far [6]. Simi-
larly, in the stomach, the Correa model indicates a stepwise process
leading to metaplastic, then early and advanced neoplastic lesions.
However, whereas the etiology of Barrett metaplasia is linked to re-
flux esophagitis, in gastric cancer, Helicobacter pylori is the single
most important risk factor.
Both diseases result from molecular alterations including activa-
tion of oncogenes and inactivation of tumor suppressor genes, which
are crucial for the sequential development from premalignant lesions
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to adenocarcinomas [3,7,8]. Aberrant methylation of CpG islands
frequently leads to inactivation and silencing of respective tumor sup-
pressor genes, thus aberrant methylation and subsequent transcrip-
tional silencing of various genes including APC, HPP1, COX-2,
DAPK, p16, and p14 have been identified in esophageal and gastric
adenocarcinomas [9–12]. Tissue inhibitor of metalloproteinase 3
(TIMP-3) is an inhibitor of metalloproteases (a group of peptidases
involved in degradation of the extracellular matrix) and was shown
to induce apoptosis and inhibit growth of tumor cells and is, thus,
considered to be a tumor suppressor [13–15]. Recently, the role of
TIMP-3 methylation was analyzed in esophageal and gastric cancers;
however, the clinical implications of loss of TIMP-3 expression has
not been addressed in these cancers [16–18].
Materials and Methods
Cell Lines and 5-aza-2′-deoxycytidine Treatment
Gastric adenocarcinoma cell lines (SNU1, AGS, MKN45, MKN28,
and N87), esophageal adenocarcinoma (EAC; OE33), and squamous
cell cancer (OE21) cell lines were obtained from American Type
Culture Collection (Manassas, VA) and Japan Cell Bank (Tokyo,
Japan) and were maintained in either F12K or RPMI-1640 media.
Incubation with 5-aza-2′-deoxycytidine was carried out as previously
described [19].
Reverse Transcription–Polymerase Chain Reaction Analysis
Conventional histologic diagnosis of serial sections was used to con-
firm the high density of cancer cells in the specimens before RNA ex-
traction; total RNA was then extracted using Nucleospin RNA L Kit
(Macherey-Nagel GmbH & Co. KG, Düren, Germany) according to
the manufacturer’s instructions [20]. Polymerase chain reaction was
performed under the following conditions: initial denaturation at
92°C for 120 seconds, 35 cycles with denaturation at 92°C for 40 sec-
onds, annealing at 56°C for 40 seconds, elongation at 72°C for 60 sec-
onds, and finally at 72°C for 7 minutes. Polymerase chain reaction
primers were designed to amplify a 457-bp cDNA fragment of the
human TIMP-3 gene: sense: 5′–CTACACCATCAAGCAGATGAAG
ATG–3′, antisense: 5′–GCTCAGGGGTCTGTGGCATTGAT–3′.
TIMP-3 mRNA levels were quantified by densitometric scanning
and normalization using β-actin cDNA fragments.
DNA Extraction and MethyLight Analysis of TIMP-3 Gene
Genomic DNA was extracted from tissues using the Nucleospin
Tissue Kit (Macherey-Nagel GmbH & Co. KG) according to the
manufacturer’s instructions and was analyzed by the MethyLight
technique after bisulfite conversion, as previously reported by Eads
et al. [21,22]. Briefly, two locus-specific polymerase chain reaction
primers flank an oligonucleotide probe with a 5′ fluorescent reporter
dye (6FAM) and a 3′ quencher dye (BHQ-1). For this analysis,
primers and probes are specifically designed to bind to bisulfite-
converted DNA, which generally span 7 to 10 CpG dinucleotides.
The gene of interest is then amplified and normalized to a reference
set [β-actin (ACTB)] to normalize for input DNA. TaqMan polymer-
ase chain reaction reactions were performed in parallel with primers
specific for the bisulfite-converted methylated sequence for a particular
locus and with the ACTB reference primers. The ratio between the
values was calculated in these two TaqMan analyses; using this ap-
proach, the degree of methylation at that locus was determined. The
extent of methylation at a specific locus was determined by the follow-
ing formula: [(gene/actb)sample: (gene/actb)SssI-treated genomic DNA] × 100.
A cutoff value of 4% gave the best discrimination between normal and
cancerous samples, as previously reported [21,22]. Therefore, samples
with ≥4% fully methylated molecules were termed methylated, whereas
samples with <4% were considered unmethylated. The primer and
probe sequences for TIMP-3 (GenBank Accession No. U14394) are:
forward primer (5′–3′): 5′–GCGTCGGAGGTTAAGGTTGTT–3′;
reverse primer (5′–3′): 5′–CTCTCCAAAA TTACCGTACGCG–3′;
probe sequence (5′–3′): 6FAM-AACTCGCTCGCCCG CCGAA-
BHQ1 (Figure 1).
Cohorts for Molecular Analysis
The tissue samples were obtained by resection from patients
(19 males, 3 females, median age: 59.9 years, range: 26–87 years)
Figure 1. Overview of the TIMP-3 amplicon locations. Map showing the amplicons used in this study in relation to the transcription start of
the TIMP-3 gene. Whereas the whole CpG island spans more than 1200 bp, the amplicon for the MethyLight assay covers 13 CpG sites
more than 155 bp proximal to the coding region. An extended amplicon for bisulfite sequencing covers 48 CpG sites (in total, 442 bp).
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with esophageal cancer (squamous cell cancer: 9 cases, adenocarci-
noma: 13 cases) and gastric cancer (20 males, 7 females; median
age: 64.4 years, range: 26–86 years). In all patients with esophageal
cancer and gastric cancer, tissue samples from cancer were obtained
for molecular analysis; in 17 of these esophageal cancer cases and all
gastric cancer cases, matched nonneoplastic tissues were also obtained
for molecular analysis from a tumor-free location which was at least
2 cm distant from the tumor and confirmed to be without any tumor
cell infiltration by histologic assessment. None of the patients with
esophageal cancer or gastric cancer underwent a preoperative radio-
or chemotherapy. In addition, tissue samples were also obtained from
14 patients with Barrett metaplasia (8 males, 6 females, median age:
69.3 years, range: 46–90 years) undergoing endoscopy for surveil-
lance of the lesion and biopsies were taken for histologic and molecu-
lar analysis. In 10 and 12 of these cases, respectively, the matched
cardia and antrum mucosa was also available for molecular analysis.
Immediately after resection, tissue samples were put in liquid nitro-
gen and stored at −80°C or were fixed in formalin for histologic
diagnosis (see below). The study was approved by the ethics com-
mittee of the University of Magdeburg and Charité, Berlin, Germany
(EA1/06/2004).
Cohorts for Immunohistochemical Analysis
For the immunohistochemical analysis two cohorts were used: co-
hort 1 (Magdeburg) consisted of 176 gastric cancer patients treated by
total or partial gastrectomy at the Otto-von-Guericke University be-
tween 1995 and 2005. Survival data were available from 68 patients
of whom 38 died during follow-up. Median follow-up time for those
patients was 20.1 months. Cohort 2 (Berlin) consisted of 171 gastric
cancer patients undergoing gastrectomy at the Charité University Hos-
pital between 1995 and 2002. In this cohort, survival data were avail-
able from 136 patients of whom 91 died during follow-up. The
median follow-up time for the patients was 31.1 months. No patient
was treated with radio- or chemotherapy preoperatively.
Tumors were classified according to Lauren [23] and guidelines
[24] of the International Union against Cancer.
Tissue Microarray
For the evaluation of TIMP-3 expression in cohort 1, tissue micro-
arrays (TMAs) were generated using a precision instrument (Beecher
Instruments, Silver Spring, MD). Six tissue cylinders of 0.6 mm in
diameter were punched from each tumor-bearing donor block and
12 tissue cylinders (six antrum and six corpus) from corresponding
nonneoplastic mucosa, constructing 20 blocks of TMAs.
Immunohistochemistry
Immunohistochemical staining of TIMP-3 was performed as pre-
viously described [19]; TIMP-3 antibody was from Chemicon Europe
(Hofheim, Germany). Evaluation of the slides was performed by two
experienced pathologists (C. R. and W. W.) who were blinded toward
patient characteristics, patient outcome, and results of the methyla-
tion analyses.
Staining Evaluation
For TMA evaluation (cohort 1), immunostaining was graded semi-
quantitatively as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong) for
each microarray spot and each tissue location (tumor, nonneoplastic
mucosa) separately. Subsequently, the immunoreactivity scores were
added for each case and each location and divided by the number
of microarray spots studied. Thereby a mean immunoreactivity score
was obtained for each individual patient and tissue site, i.e., tumor,
normal antrum mucosa, and normal corpus mucosa.
For correlation analysis and survival analysis, we decided to use
the easiest and most reproducible way of grouping the cancer cases
as either negative when no staining whatsoever was present in any of
the tissue spots evaluated or positive when a discernable staining was
present in at least one tissue spot.
Statistical Analysis
Statistics were performed with Statistical Package for the Social
Sciences version 15.0 (SPSS Inc., Chicago, IL). The different clinico-
pathologic characteristics were used as nominal variables in the
Fisher’s exact test, χ 2 test, and χ 2 test for trends. Otherwise, one-
way analysis of variance or Student’s t test was used to determine sta-
tistical difference. The survival curves were plotted using the Kaplan–
Meier method, and comparison of survival times was performed with
the log-rank test. All tests were two-sided, and P < .05 was consid-
ered statistically significant.
Results
TIMP-3 Is Frequently Methylated in Human Esophageal
and Gastric Cancers
Using the MethyLight assay, promoter methylation of TIMP-3 in
13 EACs was assessed and compared to the corresponding normal
esophageal mucosa in 8 patients. The cutoff of methylation was
selected to be a percentage of methylation ratio (PMR) of ≥4% as
previously described [21,22]. Interestingly, 9 EACs had a PMR ≥
4% (9/13), whereas TIMP-3 methylation was only detected in 1
of 8 nonneoplastic esophageal samples (P = .024; Figure 2A).
TIMP-3 methylation was less common in esophageal squamous cell
cancers (ESCC; 2 of 9 cases), whereas all corresponding matched
nonneoplastic mucosa samples exhibited a PMR < 4% (Figure 2A).
We also observed TIMP-3 methylation in 1 of 2 cases with low-
grade IEN in Barrett esophagus (Figure 2A).
Then, we studied matched samples from Barrett mucosa, cardia,
and antrum mucosa. TIMP-3methylation was frequently observed in
Barrett mucosa (6/12), matched cardia (6/10), and antrum mucosa
(7/12). Furthermore, when adjusting the methylation levels with re-
gard to the quantity of methylated CpGs per sample and entity, a
high degree of methylation was found in Barrett mucosa (mean ±
SD, 27.2 ± 33.3%) compared with the matched cardia (18.1% ±
17.3%) and antrum (6.79% ± 5.47%; Figure 2B).
Next, we studied samples from 15 gastric cancer patients. Again,
the MethyLight assay showed that TIMP-3 was more frequently
methylated in the tumor (9/15) compared with the matched non-
neoplastic mucosa (2/14, P = .021; Figure 2C ).
TIMP-3 Methylation and Expression in Esophageal and
Gastric Adenocarcinoma
Next, we analyzed the frequency of TIMP-3 methylation and ex-
pression levels in esophageal and gastric adenocarcinoma cell lines.
TIMP-3 expression was studied in 6 adenocarcinoma cell lines and
1 ESCC cell line (OE21) after incubation with the methylation in-
hibitor 5-aza-2′-deoxycytidine (Figure 3). Whereas in 4 gastric
adenocarcinoma cell lines TIMP-3 mRNA was below the detec-
tion level, SNU1, AGS, and MKN45 exhibited readily detectable
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TIMP-3 mRNA levels after treatment with 5-aza-2′-deoxycytidine.
MKN28 exhibited a loss of TIMP-3 mRNA expression despite
5-aza-2′-deoxycytidine treatment and was therefore excluded from
the methylation analysis. In N87 gastric cancer cells and the EAC
cell line OE33, TIMP-3 mRNA was constitutively expressed, and
after treatment, mRNA levels further increased. In contrast, although
the ESCC cell line (OE21) exhibited readily detectable expression
of TIMP-3, 5-aza-2′-deoxycytidine treatment did not change the
mRNA levels in these cells (Figure 3).
Using the MethyLight assay cell lines SNU1, OE33, AGS, MKN45,
and N87 showed TIMP-3 methylation before and after 5-aza-2′-
deoxycytidine treatment (not shown). Similarly, bisulfite sequencing
Figure 2. TIMP-3 gene methylation in esophageal and gastric cancer. (A) TIMP-3 gene methylation in ESCC and EAC. Matched non-
cancerous esophageal mucosa in green. Two cases with IEN in Barrett metaplasia included (IEN). (B) Levels of TIMP-3 methylation
in antral and cardia compared to Barrett metaplasia. (C) TIMP-3 gene methylation in gastric cancers and matched noncancerous gastric
mucosa. PMR (%) indicates percentage methylated reference.
Figure 3. TIMP-3 expression in cell lines. Changes of TIMP-3 mRNA
levels in esophageal and gastric cancer cell lines after incubation
with 5-aza-2′-deoxycytidine treatment. D indicates incubation with
DMSO; A, incubation with 5-aza-2′-deoxycytidine.
566 TIMP-3 in Esophageal and Gastric Adenocarcinomas Gu et al. Neoplasia Vol. 10, No. 6, 2008
of the amplicons revealed no base pair changes and confirmed the
MethyLight assay results (Figure 4). However, sequencing of a longer
fragment of the TIMP-3 (spanning 94-bp upstream and 85-bp
downstream from the included original amplicon) for SNU1 revealed
a CpG 71-bp upstream of the analyzed region, which was demethyl-
ated after 5-aza-2′-deoxycytidine treatment (Figure 4).
In 9 of 27 cases with gastric cancer, TIMP-3 mRNA was down-
regulated or lost in cancers compared with matched nonmalignant
Figure 4. Bisulfite sequencing of TIMP-3 promoter region. Results from sequencing of different clones from cancer cells incubated with
DMSO or 5-aza-2′-deoxycytidine. Sequences of the amplicons used in methylation analysis of five cell lines after incubation with 5-aza-2′-
deoxycytidine treatment and DMSO-treated controls. Reference sequence refers to the reference sequence for the TIMP-3 gene accord-
ing to GenBank. Single CpG site that turned to unmethylated after incubation with 5-aza-2′-deoxycytidine marked by vertical rectangle
(position 993).
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mucosa. TIMP-3 mRNA levels were also decreased in cancerous tis-
sues in 3 of 8 cases with EAC when compared with matched non-
cancerous tissues. Similarly, in 4 of 9 patients with ESCC, reduction
of TIMP-3 mRNA levels was present in neoplastic tissues compared
with matched normal esophageal mucosa (not shown). We observed
no statistical significant association of TIMP-3 promoter methylation
with loss or down-regulation of mRNA expression in esophageal and
gastric adenocarcinomas.
Association of Loss of TIMP-3 Protein Expression with Clinical
Characteristics of Gastric Cancer Progression
To explore the role of putative TIMP-3 losses in the development
and progression of adenocarcinoma of the stomach, we obtained
tumor samples from 347 patients with gastric cancer and assessed
the association of TIMP-3 expression in tumor cells with clinico-
pathologic characteristics of these patients. Complete loss of TIMP-3
expression was noted in 17% (cohort 1) and 27.5% (cohort 2) of
adenocarcinomas, respectively (Table 1). The remaining tumors in
both cohorts showed preserved expression of the protein, but expres-
sion varied to a considerable extent (Figure 5).
No clear-cut correlations of expression of the protein with TNM-
stage were seen. However, locally advanced metastasized tumors
tended to show higher rates of TIMP-3 loss when compared with
their locally restricted counterparts (Table 2). Interestingly, a signifi-
cant loss of TIMP-3 expression was evident in diffuse-type gas-
tric cancers in comparison to intestinal-type tumors in cohort 1 (P =
.006), which was confirmed in cohort 2 (P < .001; Table 1). Conse-
quently, in both cohorts, TIMP-3 expression correlated with tumor
grade, with poorly differentiated tumors being significantly more likely
to be TIMP-3–negative than well-differentiated ones (cohort 1: P =
.003; cohort 2: P = .012; Table 1).
In cohort 1, in which only limited data on patient survival were
available, TIMP-3 expression failed to show a statistical significant
association with overall survival time (P = .309; Figure 5). However,
those patients with TIMP-3–negative tumors tended toward short-
ened mean overall survival time (22.2 vs 43.4 months; Table 2).
In the second larger cohort, again disadvantages in overall survival
time were evident in the TIMP-3–negative patient group (19.4 vs
36.5 months) when compared with patients with preserved tumoral
TIMP-3 expression (Table 2). Interestingly, in this more representa-
tive tumor cohort, these survival differences proved to be statistically
significant (P = .040; Table 2 and Figure 6). After stratification for
Lauren type of gastric cancer, only intestinal-type gastric cancers exhib-
ited a significant difference in survival with regard to the expression or
loss of TIMP-3 expression (Figure 7). To test for independent prog-
nostic significance of TIMP-3 expression, we performed a multivariate
survival analysis including age, stage, nodal status, state of distant me-
tastasis, and grade. In this analysis, we failed to prove independent sta-
tistical significance of our marker (HR = 0.69, P = .128).
Discussion
The family of TIMPs consists of four members that specifically in-
hibit the proteolytic activity of matrix metalloproteinases [25]. TIMP-3
is secreted as a 24-kDa protein that, in contrast to other TIMP
family members, also binds to the extracellular matrix. TIMP-3 is con-
sidered a tumor suppressor [26], because TIMP-3 can inhibit tumor
growth, angiogenesis, and invasion and can promote apoptosis. Ac-
cordingly, its expression is frequently down-regulated or lost in tumor
Table 1. TIMP-3 Expression in Both Cohorts and Correlation of TIMP-3 Expression with Clinicopathological Features.
Cohort 1 Cohort 2
All Cases TIMP-3–Negative TIMP-3–Positive P All Cases TIMP-3–Negative TIMP-3–Positive P
All cases 176 (100%) 30 (17%) 146 (83%) 171 (100%) 47 (27.5%) 124 (72.5%)
Age
≤65 years 84 (47.7%) 14 (16.7%) 70 (83.3%) 1.000* 94 (55%) 25 (26.6%) 69 (73.4%) 0.864*
>65 years 92 (52.3%) 16 (17.4%) 76 (82.6%) 77 (45%) 22 (28.6%) 55 (71.4%)
Tumor stage
T1 19 (10.8%) 2 (10.5%) 17 (89.5%) 0.142† 8 (4.6%) 0 (0%) 8 (100%) 0.312†
T2 75 (42.6%) 11 (14.7%) 64 (85.3%) 80 (46.8%) 22 (27.5%) 58 (72.5%)
T3 72 (40.9%) 14 (19.4%) 58 (80.6%) 68 (39.8%) 21 (30.9%) 47 (69.1%)
T4 10 (5.7%) 3 (30%) 7 (70%) 15 (8.8%) 4 (26.7%) 11 (73.3%)
Nodal status
N0 49 (28.3%) 5 (10.2%) 44 (89.8%) 0.090† 36 (21.1%) 8 (22.2%) 28 (77.8%) 0.208†
N1 64 (37%) 12 (18.8%) 52 (81.2%) 64 (37.4%) 17 (26.6%) 47 (73.4%)
N2 37 (21.4%) 5 (13.5%) 32 (86.5%) 51 (29.8%) 14 (27.5%) 37 (72.5%)
N3 23 (13.3%) 7 (30.4%) 16 (69.6%) 20 (11.7%) 8 (40%) 12 (60%)
State of metastasis
M0 150 (85.2%) 22 (14.7%) 128 (85.3%) 0.052* 156 (91.2%) 44 (28.2%) 112 (71.8%) 0.763*
M1 26 (14.8%) 8 (30.8%) 18 (69.2%) 15 (8.8%) 3 (20%) 12 (80%)
Grade
G1 3 (1.7%) 0 (0%) 3 (100%) 0.003† 2 (1.2%) 0 (0%) 2 (100%) 0.012†
G2 49 (27.8%) 2 (4.1%) 47 (95.9%) 43 (25.1%) 6 (14%) 37 (86%)
G3 124 (70.5%) 28 (22.6%) 96 (77.4%) 126 (73.7%) 41 (32.5%) 85 (67.5%)
Lauren
Intestinal 107 (63.3%) 12 (11.2%) 95 (88.8%) 0.006‡ 90 (52.6%) 13 (14.4%) 77 (85.6%) <0.001‡
Mixed 0 (0%) / / 69 (40.4%) 27 (39.1%) 42 (60.9%)
Diffuse 62 (36.7%) 18 (29%) 44 (71%) 12 (7%) 7 (58.3%) 5 (41.7%)
P values were calculated for each cross-table correlation separately in the respective subgroups.
*Fisher’s exact test.
†χ 2 test for trends.
‡χ 2 test.
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cells [13,14,27]. The TIMP-3 gene is located on chromosome
22q12.3, a region in which loss of heterozygosity is frequently ob-
served in various cancers, such as pancreatic endocrine tumors and
secondary glioblastoma [28–30]. Interestingly, a recent study by
Bachmann et al. [15] reported that silencing of TIMP-3 gene is
also associated with 5′ CpG island hypermethylation in kidney,
brain, and colon cancers. Using the MethyLight assay, we found fre-
quent CpG island methylation of the TIMP-3 gene promoter in
Figure 5. TIMP-3 expression in gastric cancer. Immunohistochemical detection of TIMP-3 in nonneoplastic gastric foveloar epithelium
(A) and well-differentiated intestinal-type cancer (B). Poorly differentiated intestinal-type cancer (C) and diffuse-type gastric cancers (D)
frequently demonstrated loss of TIMP-3 expression. Hematoxylin counterstain. Original magnifications, ×200.
Table 2. Clinicopathological Characteristics of Gastric Cancer and Survival in Two Cohorts.
Cohort 1 Cohort 2
Cases Events Mean Survival (months) SE Log-Rank Test (P) Cases Events Mean Survival (months) SE Log-rank test (P)
Age at diagnosis
≤65 years 33 17 46.7 9.0 0.296 74 46 35.6 4.1 0.053
>65 years 35 21 25.7 5.8 62 45 28.8 4.6
Tumor stage
pT1 4 1 20.3 5.7 0.442 6 3 48.2 9.9 <0.001
pT2 33 15 40.3 7.6 65 35 42.4 4.7
pT3 28 20 30.8 7.6 53 42 23.2 4.2
pT4 3 2 13.4 4.1 12 11 7.8 2.5
Nodal status
pN0 18 4 47.5 7.3 0.001 27 15 39.3 6.5 0.001
pN1 28 16 39.1 8.4 54 33 38.5 4.9
pN2 10 8 16.9 7.8 40 31 23.7 4.7
pN3 10 8 10.3 3.3 15 12 11.5 4.4
State of metastasis
M0 56 27 44.6 7.2 0.001 124 82 33.6 3.4 0.144
pM1 12 11 11.7 3.5 12 9 14.3 4.1
Grade
G1 / / / / 0.135 1 0 / / 0.198
G2 22 9 39.8 9.0 39 23 41.5 6.3
G3 46 29 34.5 6.8 96 68 25.6 2.8
TIMP-3 expression
Negative 14 11 22.2 6.6 0.309 35 27 19.4 3.7 0.040
Positive 54 27 43.4 7.4 101 64 36.5 3.8
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Figure 7. Overall survival in diffuse and intestinal-type gastric cancer with regard to TIMP-3 expression. Kaplan–Meier curves depicting
overall survival in patients stratified for TIMP-3 expression in cohorts 2 (A, intestinal-type; B, diffuse-type) and 1 (C, intestinal-type; D,
diffuse-type). P values were calculated with a log-rank test.
Figure 6. Overall survival in dependence of TIMP-3 expression. Kaplan–Meier curves depicting overall survival in patients stratified for
TIMP-3 expression in cohorts 1 (A) and 2 (B). P values were calculated with a log-rank test.
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adenocarcinomas of esophagus and stomach. This observation con-
firms previous studies by Eads et al. [21] and Kang et al. [11], who
also reported TIMP-3 methylation in their series of esophageal or
gastric adenocarcinomas. In our analysis, only few matched normal
esophageal mucosa samples in these patients exhibited TIMP-3 gene
methylation. Further analysis in Barrett esophagus, the precancerous
lesion of EAC, revealed a high frequency of TIMP-3 gene meth-
ylation, indicating that early precancerous lesions, such as Barrett
metaplasia harbor TIMP-3 gene methylation. Thus, this epigenetic
alteration is a common event in adenocarcinomas of the stomach
and esophagus and seems to be an early molecular alteration in the
stepwise sequence leading to adenocarcinomas of the upper gastro-
intestinal tract. Consistent with our findings, recent reports by Kang
et al. [11] and Darnton et al. [12] also demonstrated an increasing
frequency of TIMP-3 gene methylation along the pathogenesis of
adenocarcinomas of the stomach and esophagus.
The loss or down-regulation of TIMP-3 expression has been linked
to TIMP-3 gene methylation in adenocarcinomas of the esophagus
and stomach in previous reports [12,31]. We also analyzed the
TIMP-3 mRNA levels after incubation with the methylation inhibi-
tor 5-aza-2′-deoxycytidine in cancer cell lines. Apart from MKN28,
TIMP-3 mRNA levels were up-regulated or restored in all cell lines,
thus confirming previous observations [12,31]. However, by bisulifte
sequencing, we did not observe a significant alteration of the meth-
ylation status of the TIMP-3 gene. Therefore, we sequenced a longer
fragment of the TIMP-3 gene (spanning 94-bp upstream and 85-bp
downstream from the included original amplicon). In SNU1 cells,
we found a CpG 71-bp upstream of the analyzed region, which was
demethylated after 5-aza-2′-deoxycytidine treatment.
Loss of TIMP-3 expression by reverse transcription–polymerase
chain reaction analysis was not consistently observed in gastric and
esophageal cancers despite the high frequency of TIMP-3 gene meth-
ylation in our series of esophageal and gastric adenocarcinomas. We
believe that the stromal expression of TIMP-3 may mask the loss of
TIMP-3 expression that we observed in our immunohistochemical
analysis [12]. So from the analysis of the cancer tissues, we cannot
clearly state that TIMP-3 methylation in gastric or esophageal can-
cers leads to gene silencing, although data from other studies point to
this association [16–18].
By immunohistochemical analysis, we observed a high frequency
of loss of TIMP-3 expression in human gastric cancers. Interestingly,
loss of TIMP-3 expression was especially frequent in diffuse-type
cancers and cancers with poor differentiation. All diffuse-type gastric
cancers and high-grade intestinal-type tumors (G3) are characterized
by a strikingly infiltrative invasion pattern with single tumor cells and
small groups of cells invading between preexisting gastric wall struc-
tures. Well and moderately differentiated intestinal-type cancers, in
contrast, tend to show a less-infiltrative cohesive pushing invasion
pattern. Our observation that loss of TIMP-3 expression is associated
with the former elegantly underscores the importance of this metallo-
proteinase inhibitor in the regulation of tissue invasion in vivo. It
seems likely that a loss of this key enzyme leads to a shift toward
enhanced proteolytic activity of the tumor cells which in turn facil-
itates single-cell tissue invasion.
Finally, we assessed the clinical impact of loss of TIMP-3 expres-
sion in esophageal and gastric cancers. Interestingly, gastric cancer
patients with loss of TIMP-3 expression experienced a shorter sur-
vival rate compared to cancers expressing TIMP-3. These data indi-
cate that loss or reduction of TIMP-3 expression is of prognostic
significance in gastric adenocarcinoma, and thus points to a role of
TIMP-3 in the progression of these cancers.
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